Currently Viewing:
Newsroom
Currently Reading
Dapagliflozin Added to Regimen Boosts Glycemic Control in Type 1 Diabetes
August 11, 2016 – Mary Caffrey
Physical Activity Lowers Risk of 5 Common Chronic Diseases
August 10, 2016 – Laura Joszt
Different Responses to Metformin? It's in the Genes, Study Finds
August 09, 2016 – Mary Caffrey
AstraZeneca Updates Digital Lifestyle Program to Include CV Health
August 08, 2016 – AJMC Staff
Regular, Moderate Exercise Best for Glucose Control in People With Pre-Diabetes
August 05, 2016 – Jackie Syrop
Studies Find Fear of Vision Loss, Diabetic Retinopathy Linked With Not Moving
August 04, 2016 – Mary Caffrey
Diabetes Drugs Take Hits in Formulary Updates
August 03, 2016 – Mary Caffrey
The Risk of T2D in Individuals With Benign Adrenal Tumors
August 02, 2016 – AJMC Staff
Advocacy Group Highlights Not-So-Winning Restaurant Combinations
August 01, 2016 – Mary Caffrey

Dapagliflozin Added to Regimen Boosts Glycemic Control in Type 1 Diabetes

Mary Caffrey
The findings of improved glycemic control but some incidence of diabetic ketoacidosis are consistent with other early findings of use of SGLT2 inhibitors in type 1 diabetes.
A study involving the SGLT2 inhibitor dapagliflozin has found that adding the therapy to insulin and liraglutide is associated with improved glycemic control for patients with type 1 diabetes (T1D). Patients also lost weight.

Findings published recently in the Journal of Clinical Endocrinology and Metabolism were based on a study of 30 patients with T1D. The use of sodium glucose co-transporter 2 (SGLT2) inhibitors for T1D patients has drawn recent interest, and research in this area was featured at a session of the American Diabetes Association in June.

All the patients in the study had been taking liraglutide along with their insulin therapy for at least 6 months. They were randomized to receive either a 10 mg dose of dapagliflozin or placebo for 12 weeks.

Researchers reported a 0.66% decrease in glycated hemoglobin (A1C) in the dapagliflozin group and no significant change in the group taking placebo. Patients taking dapagliflozin lost an average of 1.9 kg, with no additional hypoglycemia.

Results also showed significant increases in the plasma concentrations of glucagon, free fatty acids, acetoacetate, and β-hydroxybutyrate in the dapagliflozin group. However, 2 patients in taking the study group developed diabetic ketoacidosis, which was reported in a study involving another SGLT2 inhibitor, canagliflozin, in T1D patients.

At the ADA session, researchers said SGLT2 inhibitors may provide a path away from the rapid fluctuations in blood glucose, which are a hallmark of T1D.

Reference

Kuhadya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes [published online August 4, 2016]. J Clin Endocrinol Metab. 2016; http://dx.doi.org/10.1210/jc.2016-1451

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up